The significance of the expression of cell proliferation and inflammation markers in the development of acquired middle ear cholesteatoma
Abstract
Background/Aim. Permanent proliferation and periodical infection are the main clinical characteristics of acquired middle ear cholesteatoma. The aim of this study was to research immunohistochemical characteristics of the skin along with the cholesteatoma process in the nearby tissue. This research should influence further studying of etiology and development of acquired middle ear cholesteatoma. Methods. We investigated clinical, histological and immunohistochemical characteristics of cholesteatoma in 50 samples from operated patients with acquired middle ear cholesteatomas. We classified all samples according to their clinical characteristics of cholesteatoma such as bone destruction, presence of infection or cholesteatoma extension and histological characteristics of cholesteatoma such as keratinisation, inflammatory process and extracellular matrix proliferation. We used mouse monoclonal antibodies for proliferating cell nuclear antigen (MAbs for PCNA), Ki-67, COX-2, CD 4 and CD 8 lymphocytes to investigate the expression of those characteristics in the cholesteatoma and in the control skin tissue. Statistical analyses were performed using SPSS for Windows version 16.0 (SPSS, Chicago, IL, USA). We used the independent group t-test, Spearman’s correlation analysis and Mann-Whitney U test to analyze statistical analysis. Results. Expression of PCNA, Ki-67, COX-2 and CD 8 lymphocytes in more serious clinical picture of cholesteatoma was almost equal as in less serious clinical picture of cholesteatoma. There was statistically significantly higher concentration of inflammation marker CD 4 lymphocytes, both in the acquired cholesteatoma and in the skin of bony portion of the external auditory canal near fibrocartilaginous annulus in more serious clinical picture of cholesteatoma than in less serious clinical picture of cholesteatoma (p < 0.01). There was statistically significant difference of expression of PCNA, Ki-67, COX-2, CD 4 and CD 8 lymphocytes between all cholesteatoma samples and the skin of bony portion of the external auditory canal (p < 0.05) and statistically significant difference of expression of those markers between the skin of bony portion of the external auditory canal and retroauricular skin (p < 0.05). Conclusion. Inflammation of the skin of bony portion of the external auditory canal is a milestone in pathogenesis of acquired middle ear cholesteatoma. Expression of CD 4 lymphocytes can be the prognostic factor for acquired cholesteatoma clinical picture development. We found so much diversity in biological behavior through very different levels of cholesteatoma development. Expression of Ki-67 in acquired middle ear cholesteatoma is a reliable and stable marker of proliferation for acquired middle ear cholesteatoma.
References
References:
Gray JD. The chronic ear. The treatment of cholesteatoma in children. Proc R Soc Med 1964; 57: 769–71.
Sade J. Treatment of cholesteatoma and retraction pockets. Eur Arch Otorhinolaryngol 1993; 250(4): 193–9.
Kemppainen HO, Puhakka HJ, Laippala PJ, Sipilä MM, Manninen MP, Karma PH. Epidemiology and a etiology of middle ear cholesteatoma. Acta Otolaryngol 1999; 119(5): 568–72.
Starborg M, Gell K, Brundell E, Höög C. The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and hetero-chromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression. J Cell Sci 1996; 109 ( Pt 1): 143–53.
Schlüter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins.J Cell Biol 1993; 123(3): 513–22.
Raynov AM, Moon SK, Choung YH, Hong SP, Park K. Nucleop-lasm staining patterns and cell cycle-associated expression of Ki-67 in middle ear cholesteatoma.Am J Otolaryngol 2005; 26(5): 296–301.
Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 2008; 14(24): 8221–7.
Frickmann Н, Zautner АЕ, Cholesteatoma? A potential conse-quence of chronic middle ear inflammation. Otolaryngology 2012; 2(Suppl 5): 2–8.
Welkoborsky HJ. Current concepts of the pathogenesis of ac-quired middle ear cholesteatoma. Laryngorhinootologie 2011; 90(1): 38 ̶ 48; quiz 49–50. (German)
Maniu A, Harabagiu O, Perde Schrepler M, Cătană A, Fănuţă B, Mogoantă CA. Molecular biology of cholesteatoma. Rom J Morphol Embryol 2014; 55(1): 7–13.
Songu M, Altay C, Onal K, Arslanoglu S, Balci MK, Ucar M, et al. Correlation of computed tomography, echo-planar diffusion-weighted magnetic resonance imaging and surgical outcomes in middle ear cholesteatoma. Acta Otolaryngol 2015; 135(8): 776–80.
Miyahara N, Fukushima N, Hirai T, Miyoshi A, Ariki M. Clinical Features of the Pediatric Acquired Cholesteatoma Based on the Staging Criteria for Cholesteatoma 2010 Japan. Nihon Jibiinkoka Gakkai Kaiho 2016; 119(3): 181–6. (Japa-nese)
Dornelles C, Meurer L, Selaimen da Costa S, Schweiger C. Histologic description of acquired cholesteatomas: comparison between children and adults. Braz J Otorhinolaryngol 2006; 72(5): 641–8.
Aslıer M, Erdag TK, Sarioglu S, Güneri EA, Ikiz AO, Uzun E, et al. Analysis of histopathological aspects and bone destruction characteristics in acquired middle ear cholesteatoma of pediatric and adult patients. Int J Pediatr Otorhinolaryngol 2016; 82: 73–7.
Erdoglija M, Milanovic N, Colic R, Jovic M. Middle ear cholestea-toma – correlation of histological, immunohistochemical and clinical characteristics. MD-Medical Data 2014; 6(4): 315–21. (Serbian)
Li H, Jiang P, Wang L. Immunohistochemical study of the epi-thelial hyperproliferation in middle ear cholesteatoma. Zhong-hua Er Bi Yan Hou Ke Za Zhi 2002; 37(2): 118–20. (Chinese)
Liu L, Li Z, Hu M. Langerhans cells and human aural choles-teatoma. Zhonghua Er Bi Yan Hou Ke Za Zhi 1995; 30(1): 33–6. (Chinese)
Hussein MR, Sayed RH, Abu-Dief EE. Immune cell profile in invasive cholesteatomas: preliminary findings. Exp Mol Pathol 2010; 88(2): 316–23.
Ma X, Yu LS, Xia RM. Immunohistochemical discrimination of aggressivity between the cholesteatoma from different posi-tions. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2006; 41(8): 574–8. (Chinese)
Alicandri-Ciufelli M, Marchioni D, Presutti L. In response to A new theory on the pathogenesis of acquired cholesteatoma: Mucosal traction. Laryngoscope 2016; 126(1): E48–9.
Sanli A, Tezer I, Paksoy M, Aydin S, Hardal U, Ozdemir NB. Evaluation of Ki-67 expression in recurrent cases of cholesteatoma.Kulak Burun Bogaz Ihtis Derg 2007; 17(2): 65–9. (Turkish)
Huisman MA, De Heer E, Grote JJ. Sustained extracellular sig-nal-regulated kinase1/2 mitogen-activated protein kinase sig-nalling is related to increased p21 expression in cholesteatoma epithelium. Acta Otolaryngol 2005; 125(2): 130–40.
Park K, Park HJ, Chun YM. Immunohistochemical study on proliferative activity of experimental cholesteatoma. Eur Arch Otorhinolaryngol 2001; 258(3): 101–5.
Kaya E, Dag I, Incesulu A, Gurbuz MK, Acar M, Birdane L. Investigation of the presence of biofilms in chronic suppurative otitis media, nonsuppurative otitis media, and chronic otitis media with cholesteatoma by scanning electron microscopy. ScientificWorldJournal 2013; 2013: 638715.
Bjarnsholt T. The role of bacterial biofilms in chronic infec-tions. APMIS Suppl 2013; (136): 1–51.